In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare ...

We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the ...

Moderna (NASDAQ:MRNA) took a hit Tuesday as Barclays downgraded the stock from Overweight to Equal Weight, citing policy ...

Moderna reported mixed fourth quarter earnings and full-year 2024 earnings Friday. Moderna's stock was down 5% in premarket ...

Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA ...

Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

Moderna reported a larger loss than analysts had expected for the fourth quarter on Friday. The COVID vaccine maker said it ...

Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 - a sharp decline from the $2.8bn recorded in the ...

Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market open. Here’s what to ...

Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter results on Friday, posting revenue of $966 million (higher ...

Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...